Warm Autoimmune Hemolytic Anemia
15
4
7
2
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
13.3%
2 terminated out of 15 trials
50.0%
-36.6% vs benchmark
13%
2 trials in Phase 3/4
150%
3 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (15)
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
Sirolimus in the Treatment of Refractory/Relapsed wAIHA
A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)
Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)
Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA
To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).
Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia
ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia
A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)
Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia
Rituximab in Auto-Immune Hemolytic Anemia